A double-blind, randomized trial has identified specific brainwave patterns that track with the mystical and altered-consciousness experiences people report under psilocybin, the psychoactive compound in magic mushrooms. The study, which enrolled 25 healthy participants in a crossover design with placebo controls, found that psilocybin produced a distinctive shift in electrical brain activity, and that this shift correlated with subjective reports of spiritual insight and perceptual change. The findings offer researchers a measurable neural fingerprint for experiences that have, until now, been captured almost entirely through questionnaires.
What the Brainwaves Showed
Each participant received a weight-adjusted oral dose of psilocybin averaging 225 micrograms per kilogram, with a placebo administered in a separate session. Researchers recorded resting EEG at baseline and again at peak drug effect. The results, published in a recent pharmacology paper, showed that psilocybin reduced power in the theta and alpha frequency bands while boosting activity in the beta and gamma ranges. Connectivity between brain regions also increased during the psilocybin session compared to placebo.
These spectral shifts matter because theta and alpha rhythms are associated with relaxed, default-mode brain states, while beta and gamma activity tends to rise during active cognitive processing and heightened awareness. The pattern the researchers observed suggests that psilocybin disrupts the brain’s ordinary resting architecture and replaces it with a more energized, interconnected state. That state, the data indicate, maps onto what participants described when filling out the Altered States of Consciousness Questionnaire after each session, with higher ratings for insightfulness, unity, and perceptual vividness.
Measuring the Unmeasurable
Quantifying a mystical experience has been a persistent challenge for psychedelic science. The field’s standard tool is the 30-item Mystical Experience Questionnaire, or MEQ30, which was validated in pooled psilocybin trials involving 184 participants who received moderate to high doses. That validation work established that MEQ30 scores reliably predict lasting changes in attitudes, behavior, and well-being, even after controlling for the raw intensity of the drug experience. In other words, how “mystical” the session feels appears to matter more for long-term outcomes than how overwhelming or challenging it was.
The new EEG study adds a biological layer to this self-report framework. Rather than relying solely on what participants say they felt, clinicians could eventually cross-reference those accounts with real-time neural data. If a particular spectral signature consistently accompanies high MEQ30 scores, it becomes possible to identify, and perhaps even guide, the therapeutic window during a psilocybin session. That prospect remains speculative, but the correlation between EEG changes and subjective experience reported in this trial is the clearest evidence yet that the two can be linked in a controlled setting.
Earlier Evidence Built the Case
The new findings did not emerge in a vacuum. A prior placebo-controlled study of 50 healthy volunteers with high-density EEG had already reported decreased source density in the 1.5 to 20 Hz range within a cingulate and parahippocampal network during psilocybin sessions. That earlier work tied changes in low-frequency power and delta-band synchronization to self-reported spiritual experiences and insightfulness. It suggested that certain deep-brain circuits involved in memory, emotion, and self-referential thinking are especially sensitive to psilocybin’s effects.
The same group and others have used source modeling and connectivity analyses, often reported through platforms like major psychopharmacology journals, to show that psilocybin loosens the usual segregation between brain networks. Regions that typically operate semi-independently begin to communicate more freely, a pattern sometimes described as “hyperconnectivity.” In the recent EEG trial, the observed increase in functional connections across cortical regions fits this broader picture of a brain shifted into a more globally integrated mode.
Separate research using fMRI rather than EEG has shown that brain connectivity “fingerprints” can predict multidimensional psilocybin experiences, including feelings of unity, spiritual significance, and insightfulness. In those studies, patterns of connectivity across large-scale networks (such as the default mode, salience, and executive control networks) were able to forecast which participants would go on to report stronger mystical-type effects. The convergence of EEG spectral data and fMRI connectome patterns around the same subjective dimensions strengthens the case that these experiences have a consistent, detectable neural basis, rather than being artifacts of expectation or setting.
Dose, Mysticism, and Lasting Meaning
One reason the EEG signature matters is that mystical-type experiences during psilocybin sessions are not random. Earlier dose-response research demonstrated that the proportion of volunteers reaching a “complete” mystical state rises systematically with higher doses, along with long-term attributions of meaning and spiritual significance. At the highest tested doses, a majority of participants met predefined criteria for a full mystical experience, characterized by unity, transcendence of time and space, ineffability, and deeply felt positive mood.
Follow-up data from a related trial found that participants who reported psilocybin-occasioned mystical experiences continued to rate them as personally meaningful and spiritually significant 14 months later. Many ranked the session among the most significant experiences of their lives, comparable to the birth of a child or the death of a parent. These long-term appraisals were not strongly predicted by demographic factors or baseline spirituality, but they did track closely with MEQ scores, reinforcing the idea that the quality of the acute experience shapes its enduring impact.
If EEG markers can flag when a participant is entering or sustaining that state, therapists might eventually use real-time monitoring to optimize session conditions. A patient whose brainwave profile shows the characteristic theta/alpha suppression and beta/gamma surge could be identified as approaching the experiential territory most strongly linked to durable benefit, while someone whose EEG remains closer to baseline might need adjusted support, different music, or changes in dosing. In principle, this could make psilocybin-assisted therapy more precise and reproducible, reducing the variability that has sometimes complicated clinical results.
The Gap Between Healthy Volunteers and Patients
The most significant limitation of this research is its participant pool. All 25 subjects were healthy adults, and the trial was registered on ClinicalTrials.gov as NCT03853577 with a protocol focused on characterizing altered waking states of consciousness rather than treating any disorder. Psilocybin-assisted psychotherapy is being explored as a treatment for depression, anxiety, substance use, and other psychiatric conditions, but the neural dynamics of a healthy brain on psilocybin may not mirror those of a brain shaped by chronic illness, medication, or trauma.
People with mood and anxiety disorders often show baseline differences in oscillatory activity, particularly in alpha and theta bands, as well as altered connectivity within and between key networks. It is not yet clear whether the same psilocybin-induced EEG signature will emerge on top of those atypical patterns, or whether the therapeutic mechanisms in patients depend on partially different neural shifts. The current trial also used relatively short-term EEG recordings at rest, whereas clinical sessions unfold over several hours and involve complex interactions with therapists and the environment.
Another caveat is the modest sample size. With 25 participants in a crossover design, the study is well powered to detect large within-subject effects but less able to characterize subtle individual differences. The correlations between EEG changes and subjective reports, while statistically robust, still leave considerable variance unexplained. Factors such as personality traits, prior meditative or spiritual practice, and expectations about the session likely modulate both brain activity and reported experience in ways that require larger, more heterogeneous samples to disentangle.
Where the Field Goes Next
Even with these limitations, the new data provide a crucial bridge between subjective reports and objective measures. Future trials can build on this work by combining continuous EEG with more frequent in-session ratings, allowing researchers to track how moment-to-moment shifts in brain rhythms align with evolving feelings of awe, fear, insight, or surrender. Integrating EEG with fMRI in the same individuals could also clarify how surface-level oscillations relate to deeper network reconfigurations that have been linked to psychedelic therapy outcomes.
For now, the practical implications are tentative. Clinicians cannot yet look at a live EEG readout and declare that a patient is having a therapeutically optimal mystical experience. But the field is moving toward a more nuanced understanding of how psilocybin reshapes brain activity, and how those changes support the kinds of experiences people later describe as life-changing. As regulatory and clinical frameworks for psychedelic therapies continue to evolve, having measurable neural markers of key experiential states may help standardize protocols, refine dosing strategies, and ultimately make these powerful interventions safer and more effective.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
